Galectin Therapeutics (GALT) Operating Expenses (2010 - 2026)

Galectin Therapeutics has reported Operating Expenses for 17 years, with the latest figure at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 48.37% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (down 60.02% YoY), and the FY2025 full-year result was $20.1 million, down 52.67% from the prior year.
• Operating Expenses for Q1 2026 stood at $4.1 million, up from $3.4 million in the prior quarter.
• The five-year high for Operating Expenses was $12.4 million in Q4 2024, with the low at $3.4 million in Q4 2025.
• Average Operating Expenses over 5 years is $8.4 million, with a median of $9.2 million recorded in 2023.
• Year-over-year, Operating Expenses surged 57.27% in 2022 and slumped 72.92% in 2025.
• Tracing GALT's Operating Expenses over 5 years: stood at $10.6 million in 2022, then dropped by 10.08% to $9.6 million in 2023, then increased by 29.99% to $12.4 million in 2024, then tumbled by 72.92% to $3.4 million in 2025, then grew by 21.16% to $4.1 million in 2026.
• The last three Operating Expenses figures came in at $4.1 million (Q1 2026), $3.4 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.

Peer Comparison